DEA Nods to Lab's Bid for Controlled Drug Production
Published Date: 7/17/2025
Notice
Summary
Cerilliant Corporation wants to get official permission to make large amounts of certain controlled substances. This affects anyone who works with these drugs, like researchers and medicine makers. If approved, Cerilliant can start producing soon, helping labs get the materials they need without delays or extra costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Cerilliant Seeks Bulk Manufacturer Registration
Cerilliant Corporation has applied to be registered as a bulk manufacturer of certain controlled substances. If approved, Cerilliant could produce large quantities of those drugs, which the notice says would help researchers, laboratories, and medicine makers get the materials they need without delays or extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-13445, City of Holyoke Gas & Electric Department; Notice of Effectiveness of Withdrawal of Notices of Intent
The City of Holyoke Gas & Electric got their license extended for the Station No. 5 Hydroelectric Project until 2039, so they’ve officially stopped their plans to reapply right now. This means they won’t need to file new paperwork until 2034, saving time and effort for the next big step. No one objected, and the withdrawal became official on July 11, 2025.
Next: 2025-13447, South Atlantic Fishery Management Council (Council)-Public Meetings
The South Atlantic Fishery Management Council is hosting two public meetings to talk about new rules for protecting coral reefs and managing shrimp fishing. They want to create a special Rock Shrimp fishing zone near the Oculina Bank to keep habitats safe while supporting fishermen. If you fish or care about ocean habitats in the South Atlantic, these changes could affect you soon!